|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 4 (August 15), 1999:
pp. 1156-1164
Genes Encoding Tumor-Specific Antigens Are Expressed in Human Myeloma
Cells
Nicolas van Baren,
Francis Brasseur,
Danièle Godelaine,
Gérald Hames,
Augustin Ferrant,
Frédéric Lehmann,
Marc André,
Christophe Ravoet,
Chantal Doyen,
Giulio C. Spagnoli,
Marleen Bakkus,
Kris Thielemans, and
Thierry Boon
From Ludwig Institute for Cancer Research, Brussels, Belgium;
Unité de Génétique Cellulaire, Université
Catholique de Louvain, Brussels, Belgium; Cliniques Universitaires
Saint-Luc, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium;
Centre Hospitalier Notre-Dame et Reine Fabiola, Charleroi, Belgium;
Hôpital de Jolimont, Haine-St-Paul, Belgium; Cliniques
Universitaires de Mont-Godinne, Yvoir, Belgium; the Department of
Surgery, Research Division, University of Basel, Basel, Switzerland;
and Laboratorium voor Fysiologie, Vrije Universiteit Brussel, Brussels,
Belgium.
Genes of the MAGE, BAGE, GAGE, and LAGE-1/NY-ESO-1
families encode antigenic peptides that are presented by HLA class I
molecules and that are recognized on human tumors by autologous
cytolytic T lymphocytes. These genes are expressed in many solid tumor
types but not in normal tissues, except male germline cells. Because the latter cells are devoid of HLA molecules, the derived antigens are
strictly tumor-specific and should constitute safe immunogens for
cancer immunotherapy. We detected a significant expression of these
genes in a high proportion of bone marrow samples from patients with
advanced multiple myeloma. This observation provides a basis for
clinical trials aimed at inducing a cellular immune response directed
at malignant plasma cells in advanced myeloma patients.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
O. C. Goodyear, G. Pratt, A. McLarnon, M. Cook, K. Piper, and P. Moss
Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma
Blood,
October 15, 2008;
112(8):
3362 - 3372.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Condomines, D. Hose, P. Raynaud, M. Hundemer, J. De Vos, M. Baudard, T. Moehler, V. Pantesco, M. Moos, J.-F. Schved, et al.
Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis
J. Immunol.,
March 1, 2007;
178(5):
3307 - 3315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Atanackovic, J. Arfsten, Y. Cao, S. Gnjatic, F. Schnieders, K. Bartels, G. Schilling, C. Faltz, C. Wolschke, J. Dierlamm, et al.
Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation
Blood,
February 1, 2007;
109(3):
1103 - 1112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Monte, M. Simonatto, L. Y. Peche, D. R. Bublik, S. Gobessi, M. A. Pierotti, M. Rodolfo, and C. Schneider
MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents
PNAS,
July 25, 2006;
103(30):
11160 - 11165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Abdul-Rasool, S H Kidson, E Panieri, D Dent, K Pillay, and G S Hanekom
An evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes.
J. Clin. Pathol.,
March 1, 2006;
59(3):
289 - 297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jalili, S. Ozaki, T. Hara, H. Shibata, T. Hashimoto, M. Abe, Y. Nishioka, and T. Matsumoto
Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma
Blood,
November 15, 2005;
106(10):
3538 - 3545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Batchu, A. M. Moreno, S. M. Szmania, G. Bennett, G. C. Spagnoli, S. Ponnazhagan, B. Barlogie, G. Tricot, and F. van Rhee
Protein Transduction of Dendritic Cells for NY-ESO-1-Based Immunotherapy of Myeloma
Cancer Res.,
November 1, 2005;
65(21):
10041 - 10049.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Geffroy-Luseau, A. Moreau-Aubry, R. Bataille, and C. Pellat-Deceunynck
Allogeneic T lymphocytes as a source of peptide-dependent T cells specific for myeloma cells
Int. Immunol.,
September 1, 2005;
17(9):
1193 - 1200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lotz, S. A. Mutallib, N. Oehlrich, U. Liewer, E. A. Ferreira, M. Moos, M. Hundemer, S. Schneider, S. Strand, C. Huber, et al.
Targeting Positive Regulatory Domain I-Binding Factor 1 and X Box-Binding Protein 1 Transcription Factors by Multiple Myeloma-Reactive CTL
J. Immunol.,
July 15, 2005;
175(2):
1301 - 1309.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Jungbluth, S. Ely, M. DiLiberto, R. Niesvizky, B. Williamson, D. Frosina, Y.-T. Chen, N. Bhardwaj, S. Chen-Kiang, L. J. Old, et al.
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation
Blood,
July 1, 2005;
106(1):
167 - 174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. van Rhee, S. M. Szmania, F. Zhan, S. K. Gupta, M. Pomtree, P. Lin, R. B. Batchu, A. Moreno, G. Spagnoli, J. Shaughnessy, et al.
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
Blood,
May 15, 2005;
105(10):
3939 - 3944.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Azuma, T. Otsuki, K. Kuzushima, C. J. Froelich, S. Fujita, and M. Yasukawa
Myeloma Cells Are Highly Sensitive to the Granule Exocytosis Pathway Mediated by WT1-Specific Cytotoxic T Lymphocytes
Clin. Cancer Res.,
November 1, 2004;
10(21):
7402 - 7412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Wang, Y. Zhang, A. Mandal, J. Zhang, F. J. Giles, J. C. Herr, and S. H. Lim
The Spermatozoa Protein, SLLP1, Is a Novel Cancer-Testis Antigen in Hematologic Malignancies
Clin. Cancer Res.,
October 1, 2004;
10(19):
6544 - 6550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Oberthuer, B. Hero, R. Spitz, F. Berthold, and M. Fischer
The Tumor-Associated Antigen PRAME Is Universally Expressed in High-Stage Neuroblastoma and Associated with Poor Outcome
Clin. Cancer Res.,
July 1, 2004;
10(13):
4307 - 4313.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Korangy, L. A. Ormandy, J. S. Bleck, J. Klempnauer, L. Wilkens, M. P. Manns, and T. F. Greten
Spontaneous Tumor-Specific Humoral and Cellular Immune Responses to NY-ESO-1 in Hepatocellular Carcinoma
Clin. Cancer Res.,
July 1, 2004;
10(13):
4332 - 4341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. De Smet, A. Loriot, and T. Boon
Promoter-Dependent Mechanism Leading to Selective Hypomethylation within the 5' Region of Gene MAGE-A1 in Tumor Cells
Mol. Cell. Biol.,
June 1, 2004;
24(11):
4781 - 4790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, E. Anaissie, R. Walker, and J. Crowley
Treatment of multiple myeloma
Blood,
January 1, 2004;
103(1):
20 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Yakirevich, E. Sabo, O. Lavie, S. Mazareb, G. C. Spagnoli, and M. B. Resnick
Expression of the MAGE-A4 and NY-ESO-1 Cancer-Testis Antigens in Serous Ovarian Neoplasms
Clin. Cancer Res.,
December 15, 2003;
9(17):
6453 - 6460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V. Dhodapkar, J. Krasovsky, and K. Olson
T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells
PNAS,
October 1, 2002;
99(20):
13009 - 13013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Tarte, J. De Vos, T. Thykjaer, F. Zhan, G. Fiol, V. Costes, T. Reme, E. Legouffe, J.-F. Rossi, J. Shaughnessy Jr, et al.
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts
Blood,
July 30, 2002;
100(4):
1113 - 1122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chiriva-Internati, Z. Wang, E. Salati, K. Bumm, B. Barlogie, and S. H. Lim
Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma
Blood,
July 18, 2002;
100(3):
961 - 965.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Dotti, B. Savoldo, P. Yotnda, D. Rill, and M. K. Brenner
Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40+ and CD40- plasmacytoma cells
Blood,
June 17, 2002;
100(1):
200 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Zammatteo, L. Lockman, F. Brasseur, E. De Plaen, C. Lurquin, P.-E. Lobert, S. Hamels, T. Boon, and J. Remacle
DNA Microarray to Monitor the Expression of MAGE-A Genes
Clin. Chem.,
January 1, 2002;
48(1):
25 - 34.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gorschluter, C. Ziske, A. Glasmacher, and I. G. H. Schmidt-Wolf
Current Clinical and Laboratory Strategies to Augment the Efficacy of Immunotherapy in Multiple Myeloma
Clin. Cancer Res.,
August 1, 2001;
7(8):
2195 - 2204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Lim, Z. Wang, M. Chiriva-Internati, and Y. Xue
Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma
Blood,
March 1, 2001;
97(5):
1508 - 1510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Chambost, N. Van Baren, F. Brasseur, D. Godelaine, L. Xerri, S. J. Landi, I. Theate, J. Plumas, G. C. Spagnoli, G. Michel, et al.
Expression of gene MAGE-A4 in Reed-Sternberg cells
Blood,
June 1, 2000;
95(11):
3530 - 3533.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
